MDJM Stock (NASDAQ:MDJH), Trade Ideas

MDJM Ltd is a real estate service company. The company provides real estate agency services to real estate developer clients, also real estate consulting services and independent training services on an as-needed basis. It offers consulting, marketing planning, advertising services, and sales strategies to real estate clients. The company income is derived from commission-based services and minimal consulting and other services. The company has two operating segments; the real estate agent services segment and the hospitality business segment. It derives a majority of its revenue from the People's Republic of China.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ANIP

BAOS

BLCM

BTBT

BTOG

CLSK

CRKN

CTLT

EZFL

FRBK

FUBO

GDOT

GLMD

GTEC

HLTH

IDEX

IMPP

IMRN

INOD

IONM

LYEL

MARA

MDJH

MEGL

MINM

NBTX

NSSC

OKYO

OPEN

RIOT

SVFD

TNYA

TRUP

TRVN

USGO

VCIG

ZAPP

Gainers


	Trevena, Inc. (NASDAQ: TRVN) shares surged 170% to $1.74 after the company announced the approval of OLINVYK in China.


Why Tredegar Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Pre-Market Outlook

HCDI

HSCS

SVRE

Gainers


	Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) gained 105.2% to $0.8001 in pre-market trading. Bellicum Pharmaceuticals 13D filing showed Baker Bros. Advisors reported a 19.99% active stake in the company.


Why Bellicum Pharmaceuticals Shares Are Trading Higher By 105%; Here Are 20 Stocks Moving Premarket

ACMR

AFRM

AGBA

ALTI

APTX

ASNS

ATSG

BILL

CDLX

COIN

CVNA

DCFC

DKNG

DMTK

DOGZ

FNKO

FORR

FOXF

FYBR

GDYN

INVE

LASR

LEJU

LFVN

LYFT

MPLN

MPWR

MYGN

PACW

PRLB

QRTEB

RDFN

RILY

SDGR

SNGX

SPXC

TEAM

TNDM

ZION

Why Atlassian Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

MDJM Ltd

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>Carnival</strong>.</p>
<p>Looking at options history for Carnival (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) we detected 17 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 23% of the investors opened trades with bullish expectations and 70% with bearish.</p>
<p>From the overall spotted trades, 3 are puts, for a total amount of $112,041 and 14, calls, for a total amount of $468,479.</p>
<h3>Projected Price Targets</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $13.0 to $20.0 for Carnival over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In terms of liquidity and interest, the mean open interest for Carnival options trades today is 13970.25 with a total volume of 29,536.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Carnival's big money trades within a strike price range of $13.0 to $20.0 over the last 30 days.</p>
<h3>Carnival Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714159894_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CCL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$3.6</td>
<td>$3.55</td>
<td>$3.6</td>
<td>$17.00</td>
<td>$57.9K</td>
<td>1.1K</td>
<td style="text-align: right;">286</td>
</tr>
<tr>
<td>CCL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$1.31</td>
<td>$1.29</td>
<td>$1.31</td>
<td>$15.00</td>
<td>$51.3K</td>
<td>4.8K</td>
<td style="text-align: right;">465</td>
</tr>
<tr>
<td>CCL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$0.94</td>
<td>$0.92</td>
<td>$0.92</td>
<td>$20.00</td>
<td>$46.0K</td>
<td>29.7K</td>
<td style="text-align: right;">721</td>
</tr>
<tr>
<td>CCL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$1.05</td>
<td>$1.03</td>
<td>$1.03</td>
<td>$15.00</td>
<td>$41.2K</td>
<td>26.6K</td>
<td style="text-align: right;">767</td>
</tr>
<tr>
<td>CCL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$2.47</td>
<td>$2.37</td>
<td>$2.47</td>
<td>$17.00</td>
<td>$37.5K</td>
<td>3.9K</td>
<td style="text-align: right;">16</td>
</tr>
</tbody>
</table>
</p>
<h3>About Carnival</h3>
<p>Carnival is the largest global cruise company, with 92 ships in service at the end of fiscal 2023. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America; P&amp;O Cruises and Cunard Line in the United Kingdom; Aida in Germany; Costa Cruises in Southern Europe; and P&amp;O Cruises in Australia. Carnival also owns Holland America Princess Alaska Tours in Alaska and the Canadian Yukon. Carnival's brands attracted nearly 13 million guests in 2019, prior to covid-19, a level it reached again in 2023.</p>
<p>In light of the recent options history for Carnival, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Carnival's Current Market Status</h3>
<ul>
<li>With a volume of 14,396,886, the price of CCL is down -0.95% at $15.04. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 59 days.</li>
</ul>
<h3>Expert Opinions on Carnival</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $24.4.</p>
<ul>
<li>Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Carnival, targeting a price of $25. </li>
<li>Maintaining their stance, an analyst from Tigress Financial continues to hold a Buy rating for Carnival, targeting a price of $25. </li>
<li>Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Carnival, targeting a price of $23. </li>
<li>An analyst from Macquarie persists with their Outperform rating on Carnival, maintaining a target price of $24. </li>
<li>Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on Carnival with a target price of $25. </li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Carnival options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Behind the Scenes of Carnival's Latest Options Trends

<p>Financial giants have made a conspicuous bearish move on Ford Motor. Our analysis of options history for Ford Motor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) revealed 31 unusual trades.</p>
<p>Delving into the details, we found 48% of traders were bullish, while 51% showed bearish tendencies. Out of all the trades we spotted, 19 were puts, with a value of $2,250,293, and 12 were calls, valued at $651,468.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $7.82 to $17.82 for Ford Motor over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Ford Motor's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Ford Motor's whale trades within a strike price range from $7.82 to $17.82 in the last 30 days. </p>
<h3>Ford Motor Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714159889_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>F</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$0.46</td>
<td>$0.44</td>
<td>$0.46</td>
<td>$13.00</td>
<td>$427.8K</td>
<td>1.3K</td>
<td>2.0K</td>
</tr>
<tr>
<td>F</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$0.38</td>
<td>$0.37</td>
<td>$0.38</td>
<td>$12.82</td>
<td>$380.0K</td>
<td>19.8K</td>
<td>17.1K</td>
</tr>
<tr>
<td>F</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$0.57</td>
<td>$0.56</td>
<td>$0.57</td>
<td>$12.82</td>
<td>$218.9K</td>
<td>17.7K</td>
<td>6.5K</td>
</tr>
<tr>
<td>F</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/21/24</td>
<td>$0.58</td>
<td>$0.56</td>
<td>$0.57</td>
<td>$12.82</td>
<td>$190.9K</td>
<td>17.7K</td>
<td>3.1K</td>
</tr>
<tr>
<td>F</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$0.51</td>
<td>$0.47</td>
<td>$0.5</td>
<td>$12.82</td>
<td>$136.2K</td>
<td>19.8K</td>
<td>4.2K</td>
</tr>
</tbody>
</table>
</p>
<h3>About Ford Motor</h3>
<p>Ford Motor Co. manufactures automobiles under its Ford and Lincoln brands. In March 2022, the company announced that it will run its combustion engine business, Ford Blue, and its BEV business, Ford Model e, as separate businesses but still all under Ford Motor. The company has nearly 13% market share in the United States, about 11% share in the U.K., and under 2% share in China including unconsolidated affiliates. Sales in the U.S. made up about 66% of 2023 total company revenue. Ford has about 177,000 employees, including about 59,000 UAW employees, and is based in Dearborn, Michigan.</p>
<h3>Ford Motor's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 43,787,703, the F's price is down by -1.19%, now at $12.88. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 90 days.</li>
</ul>
<h3>What The Experts Say On Ford Motor</h3>
<p>In the last month, 3 experts released ratings on this stock with an average target price of $14.333333333333334.</p>
<ul>
<li>An analyst from RBC Capital has decided to maintain their Sector Perform rating on Ford Motor, which currently sits at a price target of $13. </li>
<li>An analyst from Barclays has decided to maintain their Overweight rating on Ford Motor, which currently sits at a price target of $16. </li>
<li>Consistent in their evaluation, an analyst from UBS keeps a Neutral rating on Ford Motor with a target price of $14. </li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Ford Motor with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Smart Money Is Betting Big In Ford Motor Options

<p>Financial giants have made a conspicuous bullish move on Zoetis. Our analysis of options history for Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) revealed 14 unusual trades.</p>
<p>Delving into the details, we found 57% of traders were bullish, while 35% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $216,721, and 11 were calls, valued at $668,978.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $140.0 to $170.0 for Zoetis over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Zoetis's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Zoetis's substantial trades, within a strike price spectrum from $140.0 to $170.0 over the preceding 30 days.</p>
<h3>Zoetis Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714159884_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ZTS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$4.8</td>
<td>$4.4</td>
<td>$4.4</td>
<td>$160.00</td>
<td>$220.0K</td>
<td>847</td>
<td style="text-align: right;">732</td>
</tr>
<tr>
<td>ZTS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$13.5</td>
<td>$10.9</td>
<td>$11.4</td>
<td>$165.00</td>
<td>$101.4K</td>
<td>169</td>
<td style="text-align: right;">90</td>
</tr>
<tr>
<td>ZTS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$3.4</td>
<td>$3.0</td>
<td>$3.2</td>
<td>$145.00</td>
<td>$83.5K</td>
<td>107</td>
<td style="text-align: right;">264</td>
</tr>
<tr>
<td>ZTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$2.85</td>
<td>$2.8</td>
<td>$2.8</td>
<td>$165.00</td>
<td>$78.7K</td>
<td>1.1K</td>
<td style="text-align: right;">380</td>
</tr>
<tr>
<td>ZTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$1.8</td>
<td>$1.6</td>
<td>$1.8</td>
<td>$170.00</td>
<td>$70.4K</td>
<td>833</td>
<td style="text-align: right;">431</td>
</tr>
</tbody>
</table>
</p>
<h3>About Zoetis</h3>
<p>Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.</p>
<p>Having examined the options trading patterns of Zoetis, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Zoetis's Current Market Status</h3>
<ul>
<li>Trading volume stands at 3,082,324, with ZTS's price up by 3.33%, positioned at $158.46.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 6 days.</li>
</ul>
<h3>What Analysts Are Saying About Zoetis</h3>
<p>In the last month, 3 experts released ratings on this stock with an average target price of $206.66666666666666.</p>
<ul>
<li>Consistent in their evaluation, an analyst from Stifel keeps a Buy rating on Zoetis with a target price of $195. </li>
<li>An analyst from Piper Sandler has revised its rating downward to Overweight, adjusting the price target to $195. </li>
<li>Maintaining their stance, an analyst from Barclays continues to hold a Overweight rating for Zoetis, targeting a price of $230. </li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Zoetis with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Behind the Scenes of Zoetis's Latest Options Trends

<p>Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) has outperformed the market over the past 15 years by 4.63% on an annualized basis producing an average annual return of 16.81%. Currently, Blackstone has a market capitalization of $92.87 billion. </p>
<p><strong>Buying $1000 In BX:</strong> If an investor had bought $1000 of BX stock 15 years ago, it would be worth <strong>$10,844.86</strong> today based on a price of $122.33 for BX at the time of writing.</p>
<h3>Blackstone's Performance Over Last 15 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714159824_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$1000 Invested In Blackstone 15 Years Ago Would Be Worth This Much Today

<p>Monolithic Power Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MPWR#NASDAQ">MPWR</a>) has outperformed the market over the past 5 years by 22.56% on an annualized basis producing an average annual return of 34.17%. Currently, Monolithic Power Systems has a market capitalization of $32.13 billion. </p>
<p><strong>Buying $1000 In MPWR:</strong> If an investor had bought $1000 of MPWR stock 5 years ago, it would be worth <strong>$4,390.86</strong> today based on a price of $660.34 for MPWR at the time of writing.</p>
<h3>Monolithic Power Systems's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714159818_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Here's How Much You Would Have Made Owning Monolithic Power Systems Stock In The Last 5 Years

Legal

White House Says No Timeline For How Long Menthol Decision Delayed

<p>In the midst of the meme coin super cycle frenzy, swing trader <strong>Picolas Cage</strong> has taken a stand against meme coins, arguing that they are harmful to the <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38467743/arthur-hayes-bitcoin-bull-market-not-over-urges-investors-to-left-curve-it">overall cryptocurrency ecosystem</a>.</p>
<p><strong>What Happened:</strong> "They are disinteresting from a technical perspective and don&#8217;t offer anything other than a pure ponzi," the trader writes, emphasizing their lack of substance.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr">IMO memecoins are destroying crypto.<br /><br />I still maintain the opinion that memecoins are a net negative to this space.<br /><br />They are disinteresting from a technical perspective and don&#39;t offer anything other than a pure ponzi.<br /><br />They are predatory in nature and usually create a market…</p>
<p>&mdash; Picolas Cage (@Picolas_Caged) <a href="https://twitter.com/Picolas_Caged/status/1783460696174285006?ref_src=twsrc%5Etfw">April 25, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>He criticized their predatory nature, suggesting that they create an unfair market environment where less informed participants are pitted against more knowledgeable traders.</p>
<p><strong>What's The Process:</strong> According to Picolas Cage, savvy traders exploit meme coins by accumulating large positions through liquidity pools and MEV bots without significantly impacting prices. They then promote these meme coins to their followers, creating artificial demand and enticing less experienced investors to buy in.</p>
<p>This process, he argues, perpetuates a &#8220;Player vs Player&#8221; dynamic masquerading as &#8220;Player vs Environment,&#8221; where large accounts sell off their holdings to unsuspecting individuals hoping for massive returns.</p>
<p>He also notes that meme coins divert attention away from genuine technological innovations and potential wealth-generation opportunities in the broader crypto market.</p>
<p><figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/29155259/905735A6-57D3-4874-9AA1-75D037842DB3-2.gif" alt="Benzinga Future of Digital Assets conference" class="wp-image-270548" /></a></figure></p>
<p><em>Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38460505/are-dogecoin-and-shiba-inu-primed-for-the-next-leg-up">Are Dogecoin And Shiba Inu Primed For The Next Leg Up?</a></em></p>
<p><strong>Why It Matters: </strong>Cage traces the bullish phase of meme coins back to <strong>Dogecoin's</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) previous pump cycle, fueled by &#8220;normies&#8221; using profits from <strong>GameStop</strong> stock investments to enter the crypto market and show &#8220;crypto bros&#8221; the proverbial middle finger. This, however, contrasts with the new generation of meme coins that Cage sees as purely extractive.</p>
<p>In conclusion, Picolas Cage&#8217;s critique raises important questions about the impact of meme coins on the crypto market and the risks they pose to uninformed investors.</p>
<p><strong>What's Next</strong>: The influence of meme coins and&nbsp;<a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a>&nbsp;are topics expected to be thoroughly explored at Benzinga's upcoming&nbsp;<a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a>&nbsp;event on Nov. 19.</p>
<p><em>Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38454567/trader-who-turned-15k-into-5m-predicts-these-4-meme-coins-to-emulate-the-success-of-doge-s">Trader Who Turned $15K Into $5M Predicts These 4 Meme Coins To Emulate The Success Of DOGE, SHIB, FLOKI</a></em></p>
<p><em>This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.</em></p>
<p><em>Image: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

Meme Coins Are 'A Pure Ponzi' And 'Destroying Crypto,' Says Trader Who Thinks Dogecoin Was Different

Macro Economic Events

WIIM

Economics

iShares MSCI Hong Kong Index Fund is trading higher amid strength in Chinese stocks.

<p><strong>ImmunityBio, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) shares are trading higher Friday after the company announced overall survival results<a href="https://www.benzinga.com/news/24/04/38424671/why-teradyne-shares-are-trading-higher-by-over-8-here-are-20-stocks-moving-premarket"> in its QUILT 3.055 study.</a></p>
<p><strong>The Details:</strong></p>
<p>ImmunityBio said the QUILT 3.055 trial <a href="https://www.benzinga.com/pressreleases/24/04/b38421500/immunitybio-announces-positive-overall-survival-results-of-anktiva-combined-with-checkpoint-inhibi">shows</a> median overall survival almost double that of standard of care chemotherapy in 2nd- and 3rd-line non-small cell lung cancer (NSCLC) patients whose cancer did not respond to checkpoint inhibitors with or without chemotherapy. </p>
<p>"The results we noted with the completion of the QUILT 3.055 basket trial across multiple tumor types in patients with late-stage cancers for whom standard of care plus checkpoints failed, validates our hypothesis that orchestration of NK cells with killer T cells and memory T cells could result in meaningful clinical improvements to current standards of care," said Patrick Soon-Shiong, M.D., CSO of ImmunityBio.&nbsp;</p>
<p>The FDA <a href="https://www.benzinga.com/general/biotech/24/04/38380405/fda-approves-immunitybios-bladder-cancer-drug-stock-rallies">approved</a> the company's Anktiva plus Bacillus Calmette-Guérin (BCG) for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) on Monday.&nbsp;</p>
<p>ImmunityBio shares are moving on heavy trading volume Friday. According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, more than 26.6 million shares have been traded in the session, compared to the stock&#8217;s 100-day average of 4.774 million shares.</p>
<p><em>Related News: </em><a href="https://www.benzinga.com/news/24/04/38360358/whats-going-on-with-luxury-ev-maker-lucids-stock"><em>What&#8217;s Going On With Luxury EV-Maker Lucid&#8217;s Stock?</em></a></p>
<h2 class="wp-block-heading">How To Buy IBRX Stock: </h2>
<p>By now you're likely curious about how to participate in the market for ImmunityBio &#8211; be it to purchase shares, or even attempt to bet against the company.</p>
<p>Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. </p>
<p>If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.</p>
<p><strong>IBRX Price Action:</strong> According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, ImmunityBio shares are up 48% at $7.56 at the time of publication Friday.</p>
<p><em>Image: Akava Photo</em> <em>from Pixabay</em></p>


IBRX

What's Going On With ImmunityBio Stock?

PALL

Palladium is trading lower amid a rise in the US dollar.

Contracts

Management

Global

GATX

Unifor Local 21-A Bargaining Committee Reached 4-Year Tentative Collective Agreement With GATX Rail Canada In Red Deer, Alberta

PYPL

PayPal shares are trading higher amid overall market strength. The company will report Q1 earnings next week.

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>Trade Desk</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with TTD, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 15 uncommon options trades for Trade Desk.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 40% bullish and 53%, bearish.</p>
<p>Out of all of the special options we uncovered, 3 are puts, for a total amount of $126,380, and 12 are calls, for a total amount of $755,000.</p>
<h3>What's The Price Target?</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $75.0 to $105.0 for Trade Desk over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Trade Desk's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Trade Desk's whale trades within a strike price range from $75.0 to $105.0 in the last 30 days. </p>
<h3>Trade Desk Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714158949_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$21.6</td>
<td>$21.45</td>
<td>$21.45</td>
<td>$82.50</td>
<td>$117.9K</td>
<td>2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/26/24</td>
<td>$3.55</td>
<td>$3.0</td>
<td>$3.05</td>
<td>$82.00</td>
<td>$92.7K</td>
<td>1.6K</td>
<td style="text-align: right;">22</td>
</tr>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/26/24</td>
<td>$3.95</td>
<td>$3.25</td>
<td>$3.3</td>
<td>$82.00</td>
<td>$88.1K</td>
<td>1.6K</td>
<td style="text-align: right;">327</td>
</tr>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/10/24</td>
<td>$3.9</td>
<td>$3.8</td>
<td>$3.85</td>
<td>$90.00</td>
<td>$77.0K</td>
<td>1.0K</td>
<td style="text-align: right;">696</td>
</tr>
<tr>
<td>TTD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/10/24</td>
<td>$3.8</td>
<td>$3.75</td>
<td>$3.8</td>
<td>$90.00</td>
<td>$75.6K</td>
<td>1.0K</td>
<td style="text-align: right;">495</td>
</tr>
</tbody>
</table>
</p>
<h3>About Trade Desk</h3>
<p>The Trade Desk provides a self-service platform that helps advertisers and ad agencies programmatically find and purchase digital ad inventory (display, video, audio, and social) on different devices like computers, smartphones, and connected TVs. It utilizes data to optimize the performance of ad impressions purchased. The firm's platform is referred to as a demand-side platform in the digital ad industry. The firm generates its revenue from fees based on a percentage of what its clients spend on advertising.</p>
<p>Following our analysis of the options activities associated with Trade Desk, we pivot to a closer look at the company's own performance.</p>
<h3>Trade Desk's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 1,909,795, the TTD's price is up by 2.12%, now at $85.11. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 12 days.</li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Trade Desk options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


This Is What Whales Are Betting On Trade Desk

<p>Deep-pocketed investors have adopted a bullish approach towards Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in GILD usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Gilead Sciences. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 77% leaning bullish and 22% bearish. Among these notable options, 4 are puts, totaling $495,628, and 5 are calls, amounting to $213,111.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $50.0 to $68.0 for Gilead Sciences during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Gilead Sciences's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Gilead Sciences's significant trades, within a strike price range of $50.0 to $68.0, over the past month.</p>
<h3>Gilead Sciences Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714158944_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>GILD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$10.5</td>
<td>$7.1</td>
<td>$9.2</td>
<td>$67.50</td>
<td>$367.9K</td>
<td>162</td>
<td>400</td>
</tr>
<tr>
<td>GILD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$3.0</td>
<td>$2.81</td>
<td>$2.81</td>
<td>$50.00</td>
<td>$70.2K</td>
<td>662</td>
<td>254</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$1.49</td>
<td>$1.43</td>
<td>$1.49</td>
<td>$67.50</td>
<td>$59.7K</td>
<td>405</td>
<td>556</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$0.51</td>
<td>$0.46</td>
<td>$0.51</td>
<td>$68.00</td>
<td>$51.1K</td>
<td>2.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>GILD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/21/24</td>
<td>$2.63</td>
<td>$2.59</td>
<td>$2.62</td>
<td>$65.00</td>
<td>$36.5K</td>
<td>283</td>
<td>292</td>
</tr>
</tbody>
</table>
</p>
<h3>About Gilead Sciences</h3>
<p>Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.</p>
<p>After a thorough review of the options trading surrounding Gilead Sciences, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Gilead Sciences's Current Market Status</h3>
<ul>
<li>With a trading volume of 8,730,709, the price of GILD is up by 0.77%, reaching $65.78.</li>
<li>Current RSI values indicate that the stock is may be oversold.</li>
<li>Next earnings report is scheduled for 97 days from now.</li>
</ul>
<h3>What The Experts Say On Gilead Sciences</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $82.2.</p>
<ul>
<li>Maintaining their stance, an analyst from Oppenheimer continues to hold a Outperform rating for Gilead Sciences, targeting a price of $105. </li>
<li>Maintaining their stance, an analyst from Morgan Stanley continues to hold a Equal-Weight rating for Gilead Sciences, targeting a price of $78. </li>
<li>Consistent in their evaluation, an analyst from TD Cowen keeps a Buy rating on Gilead Sciences with a target price of $85. </li>
<li>Consistent in their evaluation, an analyst from RBC Capital keeps a Sector Perform rating on Gilead Sciences with a target price of $74. </li>
<li>An analyst from HSBC has elevated its stance to Hold, setting a new price target at $69. </li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Gilead Sciences with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


GILD

Gilead Sciences Unusual Options Activity

<p>Deep-pocketed investors have adopted a bearish approach towards Pinterest (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in PINS usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for Pinterest. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 45% leaning bullish and 54% bearish. Among these notable options, 3 are puts, totaling $263,130, and 8 are calls, amounting to $428,002.</p>
<h3>What's The Price Target?</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $27.0 to $40.0 for Pinterest over the recent three months. </p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>In today's trading context, the average open interest for options of Pinterest stands at 4200.0, with a total volume reaching 5,646.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Pinterest, situated within the strike price corridor from $27.0 to $40.0, throughout the last 30 days.</p>
<h3>Pinterest Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714158937_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>PINS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$5.5</td>
<td>$5.35</td>
<td>$5.45</td>
<td>$35.00</td>
<td>$152.0K</td>
<td>4.6K</td>
<td>279</td>
</tr>
<tr>
<td>PINS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/03/24</td>
<td>$1.4</td>
<td>$1.29</td>
<td>$1.37</td>
<td>$32.00</td>
<td>$123.0K</td>
<td>2.8K</td>
<td>2.6K</td>
</tr>
<tr>
<td>PINS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$0.85</td>
<td>$0.83</td>
<td>$0.86</td>
<td>$30.00</td>
<td>$111.1K</td>
<td>10.8K</td>
<td>1.4K</td>
</tr>
<tr>
<td>PINS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$3.55</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$40.00</td>
<td>$62.3K</td>
<td>13.0K</td>
<td>195</td>
</tr>
<tr>
<td>PINS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$2.03</td>
<td>$1.97</td>
<td>$2.02</td>
<td>$37.00</td>
<td>$57.5K</td>
<td>936</td>
<td>301</td>
</tr>
</tbody>
</table>
</p>
<h3>About Pinterest</h3>
<p>Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from cooking recipes to travel destinations. Founded in 2010, the platform consists of a largely female audience, which accounts for roughly two thirds of its nearly 500 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features. About 20% of users reside in the US and Canada, but the region accounted for about 80% of revenue in 2023.</p>
<p>In light of the recent options history for Pinterest, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is Pinterest Standing Right Now?</h3>
<ul>
<li>With a trading volume of 8,051,867, the price of PINS is up by 3.91%, reaching $33.91.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 4 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Pinterest</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $40.0.</p>
<ul>
<li>An analyst from Keybanc persists with their Overweight rating on Pinterest, maintaining a target price of $40. </li>
</ul>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Pinterest options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


PINS

Pinterest's Options: A Look at What the Big Money is Thinking

Stock Split

ATXI

Avenue Therapeutics shares are trading lower. The company recently announced a 1-for-75 reverse stock split of its common stock.

SMXT

SolarMax Technology shares are trading higher. The stock may be rebounding after falling last week.

GOOG

GOOGL

Google Files Motion For Summary Judgment In U.S. Adtech Case Led By Justice Dept

<p><strong>Intel Corp</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) stock fell after reporting a first-quarter (Q1) revenue miss and weak <a href="https://www.benzinga.com/quote/INTC/guidance">Q2 EPS guidance</a>.</p>
<p>The company&#8217;s quarterly earnings of 18 cents per share beat the consensus estimate by 28.57%. However, sales of $12.72 billion missed estimates by 0.44%.</p>
<p><em>Related: <a href="https://www.benzinga.com/news/earnings/24/04/38444720/intel-shares-fall-on-q1-revenue-miss-weak-q2-eps-guidance">Intel Shares Fall On Q1 Revenue Miss, Weak Q2 EPS Guidance</a></em></p>
<p>CEO Pat Gelsinger remains confident in company&#8217;s future, proclaiming &#8220;Intel is back.&#8221;</p>
<p>Here's what analysts have to say about the earnings report.</p>
<ul>
<li>JPMorgan Chase analyst Harlan Sur reiterated Underweight on Intel stock, reducing the price target from $37 to $35 a share.</li>
<li>Goldman Sachs analyst Toshiya Hari maintains his Sell rating on the stock, reducing the price target from $39 to $34.</li>
<li>Oppenheimer analyst Rick Schafer maintained his Perform rating on the stock without stating a price target.</li>
<li>Needham analyst N. Quinn Bolton, CFA reiterated Hold with no price target on the stock.</li>
<li>Wedbush analyst Matt Bryson rates the stock Neutral with his 12-month price target on the stock down from $40 to $32.50 a share.</li>
<li>BofA Securities analyst Vivek Arya reiterated his Neutral rating on the stock, while lowering price target from $44 to $40.</li>
<li>Mizuho Securities analyst Vijay Rakesh rates the stock a Buy with price target lowered from $55 to $45 a share.</li>
</ul>
<p><em>Also Read: <a href="https://www.benzinga.com/news/24/04/38447614/intel-ceo-said-foundry-business-will-see-sequential-improvement-in-every-quarter-till-2030-conf-call">Intel CEO Said Foundry Business Will See Sequential Improvement In Every Quarter Till 2030- Conf Call</a></em></p>
<p><strong>JPMorgan</strong>: According to Sur, Intel&#8217;s guidance suggests a slow recovery for PC and data center segments, requiring a strong second half for full-year outlook. There appear to be confidence issues in core compute and diversification initiatives. </p>
<p>Customer foundry revenue was lower than expected in Q1, but product and technology pipeline remains strong. The company&#8217;s roadmap milestones are on track, with new products like Sierra Forest and Granite Rapids ramping up. Overall, while 2Q guidance is muted, there is optimism for a gradual recovery in general compute demand but Intel &#8220;<strong>will be an underperformer relative to the group</strong> over the next 12-18 months,&#8221; Sur says.</p>
<p><strong>Goldman Sachs</strong>: Intel&#8217;s 2Q24 revenue and non-GAAP EPS guidance were lower than expected, attributed to the delayed recovery in traditional server demand now expected in H2. This delay is due to Cloud and Enterprise customers prioritizing AI infrastructure spending. &#8220;AI prioritization continues to weigh on traditional server demand&#8221; said Hari.</p>
<p>Goldman Sachs remains &#8220;encouraged by Intel's progress in Accelerating Computing&#8221;, particularly with the launch of Gaudi3. However, it faces challenges in maintaining its share in the Data Center Compute market against competitors like <strong>Nvidia Corp </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and <strong>Arm Holdings PLC</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>).</p>
<p><strong>Oppenheimer</strong>: &#8220;We remain on sidelines as turnaround efforts take root,&#8221; said Schafer. He attributed Intel&#8217;s weaker Q1 performance to weaker demand and the sunsetting of non-core and traditional packaging. </p>
<p>Management sees Q1 as the bottom, expecting quarter-over-quarter growth throughout the year. PC and data center (DC) sales are expected to be flat in Q2, with DC leading in the second half due to the ramp of the Gaudi3 accelerator and cyclical recovery in other segments. </p>
<p>DC is expected to be up about 25% this year. Despite optimism, Intel&#8217;s roadmap and technology leadership are concerns for Schafer. While constructive on the data center outlook, caution remains regarding PC unit growth.</p>
<p><strong>Needham</strong>: Bolton&#8217;s Hold rating is due to Intel&#8217;s high valuation, declining revenue estimates, growing competition, and distant IFS revenue contributions, &#8220;all setting up for a <strong>more difficult road ahead</strong>&#8220;. </p>
<p>Intel faces challenges in the data center market, said Bolton, with wallet share shifting to AI-compute and competition from new architectures like ARM-based CPUs and evolving ASICs. While losses in Desktop and Notebook share have slowed, positive PC trends are insufficient to support INTC&#8217;s CY24 PC unit TAM.</p>
<p><strong>Wedbush</strong>: Intel Corp is &#8220;still a work in progress,&#8221; said Bryson. He notes that Intel&#8217;s guidance for >$500M in Habana sales in 2H&#8217;24 was below expectations, despite prior commentary suggesting a larger backlog and increased AI accelerator spending. </p>
<p>While Sierra Forrest and Granite Rapids are on track for release, Bryson sees their impact on Intel&#8217;s share and revenues being modest. Additionally, Meteor Lake experienced increased demand in CQ1, with units expected to double in CQ2, but supply constraints are hindering Intel&#8217;s ability to meet this demand as it ramps up wafer level assembly.</p>
<p>Wedbush also thinks &#8220;the recent pessimism weighing on the stock is arguably overdone.&#8221; But, analysts &#8220;still aren&#8217;t comfortable yet in getting more constructive around Intel.&#8221;</p>
<p><strong>BofA Securities</strong>: Arya noted &#8220;higher costs, lower growth, tough competition,&#8221; as three key attributes identifiable with Intel&#8217;s Q1 earnings report and future outlook.</p>
<p>Intel&#8217;s Q1 earnings met expectations, but Q2 guidance disappointed due to high costs. While Arya sees the company&#8217;s strong enterprise position and US manufacturing assets offering potential, limited AI exposure could hamper growth. Q2 sales missed targets amid weak macro demand. </p>
<p>However, Intel anticipates a strong second half driven by cyclical improvements, AI PC growth, and positive enterprise trends. The company is focusing on the Gaudi3 ramp, CHIPS grants, and cost reductions to improve profitability. Challenges include losing server market share and competition in AI accelerators. Arya sees Intel&#8217;s future success depending on leveraging manufacturing synergies and managing competition from <strong>Taiwan Semiconductor Manufacturing Co Ltd</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>).</p>
<p><strong>Mizuho Securities</strong>: &#8220;We remain positive on INTC given stable compute server share, Sierra Forest and Granite Rapids product ramps ahead, and valuation with low expectations,&#8221; said Rakesh.</p>
<p>According to Rakesh, Intel&#8217;s data-centric AI (DCAI) segment remains flat as the company plays catch-up with peers, with the Gaudi3 ramp in 2H expected to contribute but still at a small scale. </p>
<p>Intel&#8217;s data center (DC) is estimated to grow by 4% y/y in 2024, compared to Nvidia&#8217;s consensus estimate of 102% y/y growth. </p>
<p>Intel is ramping its foundry business, adding external customers and anticipating margins to trough in 2024 before a stronger ramp in 2025. Despite a disappointing June quarter guide, Rakesh believes new product ramps and stable server share, combined with low expectations, could limit downside as Intel trades at a lower P/S multiple compared to <strong>Advanced Micro Devices Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) and Nvidia.</p>
<p><em>Read Next: <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/04/38467013/tech-stocks-rebound-as-magnificent-7-roar-on-strong-earnings-energy-giants-tumble-wh">Tech Stocks Rebound As Magnificent 7 Roar On Strong Earnings, Energy Giants Tumble: What&#8217;s Driving Markets Friday?</a></em></p>
<p><em>Image: Shutterstock</em></p>


Analyst Color

Earnings

Analyst Ratings

Tech

INTC

NVDA

Intel 'Still A Work In Progress' As 'Turnaround Efforts Take Root,' Analysts Say After Q1 Disappointment

<p><strong>Optimism's</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">OP</a>) price has decreased 4.11% over the past 24 hours to <strong>$2.35</strong>. This is contrary to the coins performance over the past week where it has experienced an up-trend of 3.0%, moving from $2.28 to its current price.</p>
<p>The chart below compares the price movement and volatility for Optimism over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714158155_0.png" alt="price_chart" /></p>
<p>The trading volume for the coin has decreased 22.0% over the past week, while the overall circulating supply of the coin has increased 0.25% to over 1.05 billion. This puts its current circulating supply at an estimated 24.34% of its max supply, which is 4.29 billion. The current market cap ranking for OP is #50 at $2.46 billion.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1714158155_1.png" alt="supply_and_vol" /></p>
<p><a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Cryptocurrency Optimism Decreases More Than 4% Within 24 hours

Compass, The Real Brokerage, MDJM in real estate movers

MDJM Ltd (MDJH) stock is lower by -36.65% over the last 12 months. InvestorsObserver's proprietary ranking system, gives MDJH stock a score of  0 out of a possible 100. That rank is mainly influenced by a short-term technical score of 0. MDJH's rank also includes a long-term technical score of 0.  MDJH has an Overall Score

Is MDJM Ltd (MDJH) Stock a Smart Investment Thursday?

Omega Healthcare Investors, Altisource Portfolio, Leju in real estate gainers

MDJM Ltd (MDJH) stock has fallen -3.66% over the last 12 months. InvestorsObserverâ€&#x2122;s proprietary ranking system, gives MDJH stock a score of  0 out of a possible 100. That rank is chiefly influenced by a short-term technical score of 0. MDJH's rank also includes a long-term technical score of 0.  MDJH has an Overall Score

Is MDJM Ltd (MDJH) Stock Worth a Buy Friday?

Arbor Realty Trust among real estate gainers, Digital Realty Trust in losers

Uniti Group among real estate gainers, Anywhere Real Estate in losers

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Pre-market stock movers are worth diving into on Tuesday as we check out all of the biggest changes and the news behind them!</p>



<p>Moving stocks this morning are earnings reports, an acquisition agreement, proposed public offerings and more.</p>



<p>Let&rsquo;s get into that news below!</p>



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li><strong>Dynatronics </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/dynt-stock-quote/"><strong>DYNT</strong></a>) stock is rocketing more than 97% alongside heavy pre-market trading.</li>



<li><strong>Dragonfly Energy</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/dfli-stock-quote/"><strong>DFLI</strong></a>) shares are soaring close to 55% after releasing its <a href="https://www.nasdaq.com/press-release/dragonfly-energy-reports-fourth-quarter-2023-and-full-year-financial-results-2024-04">Q4 2023 earnings report</a>.</li>



<li><strong>Macatawa Bank</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/mcbc-stock-quote/"><strong>MCBC</strong></a>) stock is surging over 38% after <a href="https://www.globenewswire.com/news-release/2024/04/15/2863147/11955/en/Wintrust-Financial-Corporation-and-Macatawa-Bank-Corporation-Announce-Plans-to-Merge.html">signing an acquisition agreement</a>.</li>



<li><strong>WiSA Technologies</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/wisa-stock-quote/"><strong>WISA</strong></a>) shares are rising more than 26% <a href="https://www.nasdaq.com/press-release/wisa-technologies-announces-reverse-stock-split-2024-04-10">following a reverse stock split</a>.</li>



<li><strong>Mobilicom </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/mob-stock-quote/"><strong>MOB</strong></a>) stock is gaining over 21% on plans to show off an <a href="https://www.nasdaq.com/press-release/mobilicom-to-unveil-unprecedented-comprehensive-solution-for-uncrewed-vehicle-systems">uncrewed vehicle system</a>.</li>



<li><strong>HNR Acquisition</strong> (NYSEMKT:<a href="https://investorplace.com/stock-quotes/hnra-stock-quote/"><strong>HNRA</strong></a>) shares are increasing more than 18% without any clear news this morning.</li>



<li><strong>Shuttle Pharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/shph-stock-quote/"><strong>SHPH</strong></a>) stock is climbing over 18% despite a lack of news.</li>



<li><strong>Taoping </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/taop-stock-quote/"><strong>TAOP</strong></a>) shares are getting a more than 16% boost without any obvious news to report.</li>



<li><strong>Global Gas</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/hgas-stock-quote/"><strong>HGAS</strong></a>) stock is jumping over 16% on Tuesday morning.</li>



<li><strong>Kaixin </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/kxin-stock-quote/"><strong>KXIN</strong></a>) shares are up more than 14% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li><strong>Ryvyl </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/rvyl-stock-quote/"><strong>RVYL</strong></a>) stock is diving over 29% on a <a href="https://www.nasdaq.com/press-release/ryvyl-inc.-announces-launch-of-proposed-underwritten-public-offering-2024-04-15">proposed public offering</a>.</li>



<li><strong>Calidi Biotherapeutics</strong> (NYSEMKT:<a href="https://investorplace.com/stock-quotes/cldi-stock-quote/"><strong>CLDI</strong></a>) shares are tumbling more than 22% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318234211&amp;type=PDF&amp;symbol=CLDI&amp;cdn=ab45db11645ce0b64dd38dde47e4a59d&amp;companyName=Calidi+Biotherapeutics+Inc.&amp;formType=S-1%2FA&amp;formDescription=%5BAmend%5D+General+form+for+registration+of+securities+under+the+Securities+Act+of+1933&amp;dateFiled=2024-04-15">proposed public offering</a>.</li>



<li><strong>Inovio Pharmaceuticals</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/ino-stock-quote/"><strong>INO</strong></a>) stock is taking an over 22% beating after <a href="https://finance.yahoo.com/news/inovio-announces-pricing-approximately-36-223900148.html">pricing an underwritten offering</a>.</li>



<li><strong>MDJM </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/mdjh-stock-quote/"><strong>MDJH</strong></a>) shares are sliding more than 15% on Tuesday morning.</li>



<li><strong>Addex Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/adxn-stock-quote/"><strong>ADXN</strong></a>) stock is dropping over 12% this morning.</li>



<li><strong>Qilian </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/qli-stock-quote/"><strong>QLI</strong></a>) shares are decreasing more than 10% today.</li>



<li><strong>Indonesia Energy</strong> (NYSEMKT:<a href="https://investorplace.com/stock-quotes/indo-stock-quote/"><strong>INDO</strong></a>) stock is falling over 10% this morning.</li>



<li><strong>US Energy</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/useg-stock-quote/"><strong>USEG</strong></a>) shares are slipping more than 10% on Tuesday.</li>



<li><strong>Poseida Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/pstx-stock-quote/"><strong>PSTX</strong></a>) stock is dipping over 9% today.</li>



<li><strong>OMNIQ </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/omqs-stock-quote/"><strong>OMQS</strong></a>) shares close out our pre-market stock movers down more than 9%.</li>
</ol><p><em>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-april-16th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>